Video Library

Empowering the Patient Voice: Genomic Testing and Cancer Care Decisions
In this roundtable discussion presented by AONN+ and supported by Exact Sciences, a panel of experts discuss the critical role of nurse navigators in educating cancer patients about genomic testing and how to interpret the results.
Barriers to Care for Multiple Myeloma Patients
Patients face multiple challenges that pose barriers to their care.
PYLARIFY and Next-Generation Imaging
Dr Neal Shore elaborates on the ability of PYLARIFY® (piflufolastat F 18) to detect metastases and the practical aspects of next-generation imaging.
PSMA-Targeted Imaging for Prostate Cancer Treatment
Dr Neal Shore discusses the rationale of prostate-specific membrane antigen (PSMA) PET/CT to guide prostate cancer treatment.
A New Era of Treatment Options for Patients with Advanced Renal-Cell Cancer
Combinations of agents have replaced sunitinib as first-line therapy for advanced renal-cell cancer. Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their best practices for helping patients get the most benefit out of combination therapy for their advanced renal-cell cancer diagnosis.
Overview of Current Imaging Modalities in Prostate Cancer
Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY® (piflufolastat F 18).
Quality of Life with Combination Therapy in Advanced Renal-Cell Cancer
Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss strategies for addressing patients’ concerns about how combination therapy may impact their activities of daily living and quality of life.
The Impact of Real-World Data on Efficacy and Safety of Agents for Advanced Renal-Cell Cancer
The last 10 to 15 years has seen important advances in the management of advanced renal-cell cancer. Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss how real-world efficacy and safety data influence the conversations they have with their patients with advanced renal-cell carcinoma regarding treatment options.
Educating Patients About First-Line Treatment Options for Advanced Renal-Cell Carcinoma
Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their approach to conversations with patients and families regarding first-line therapy for advanced renal-cell carcinoma. They also describe what resources they share with patients to help them after the initial consultation.
Advanced Care Practitioners Take a Lead in Improving Quality of Life and Patient Satisfaction for Cancer Patients
Maintaining quality of life for cancer patients means different things to different cancer patients. However, the conversation starts with helping patients manage their expectations regarding their therapy and how it will impact their quality of life. Please join Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, as they examine the many ways that they collaborate with their oncology team colleagues to assess and review how an individual patient’s treatment regimen is influencing that patient’s quality of life.
Talking to Cancer Patients About Combination Chemotherapy
The practice of using combinations of drugs in chemotherapy is not new and continues to evolve to include immune checkpoint inhibitors. Drug combinations can be more effective than single-agent therapy and may also reduce the risk of developing resistance. However, combining multiple drugs may increase the risk of drug interactions. Please join Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, as they discuss how they have a conversation with their patients about the benefits and risks of using drug combinations in anticancer therapy.
Advanced Care Practitioners Have Best Practices to Help Patients Be Compliant with Their Chemotherapy
Although chemotherapy is effective in combating cancer, its full benefits are often not realized because many patients do not take their medications as prescribed. There are many factors that contribute to poor medication adherence, including communication barriers, adverse events, and factors that are related to the therapy, such as prescription of complex drug regimens. Because barriers to medication adherence are complex and varied, solutions to improve adherence must also be multifactorial. Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their best practices to help patients adhere to their chemotherapy regimens.
Page 1 of 8
Results 1 - 12 of 86

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code